Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double Blind, Placebo Controlled "First-in-human" Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-677 ( 100 mg, 200 mg, 400 mg and 600 mg ) in Healthy Young Male Volunteers

NCT02639975 is registered in ClinicalTrials.gov with Palobiofarma SL as lead sponsor.

NCT NCT02639975
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02639975 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double Blind, Placebo Controlled "First-in-human" Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-677 ( 100 mg, 200 mg, 400 mg and 600 mg ) in Healthy Young Male Volunteers
Lead sponsor
Palobiofarma SL
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2015
Completion date
June 30, 2016
Enrollment
32 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

glaucoma